Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.45 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | MET | P08581 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | DHFR | P00374 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18251091 | 0.84 | TLR8 (0.49) | KMT2AHTTTLR8METKDM4E | |
| SCHEMBL23653413 | 0.82 | TLR8 (0.50) | KMT2AHTTTLR8METDHFR | |
| SCHEMBL3146860 | 0.80 | KMT2A (0.46) | KMT2AHTTMETMEN1POLB | |
| SCHEMBL188693 | 0.80 | GRM5 (0.47) | KMT2AHTTGRM5KDM4EHSD17B10 | |
| SCHEMBL9255 | 0.80 | HTT (0.54) | KMT2AHTTTLR8METMAPT | |
| SCHEMBL28651724 | 0.80 | ALDH1A1 (0.48) | KDM4EHSD17B10ALDH1A1POLBMAPK1 | |
| SCHEMBL3142527 | 0.79 | BIRC5 (0.42) | KMT2AHTTTLR8METKDM4E | |
| SCHEMBL612377 | 0.78 | GRM5 (0.49) | KMT2AHTTGRM5KDM4EHSD17B10 | |
| SCHEMBL18072070 | 0.78 | NOS3 (0.52) | KMT2ATLR8GRM5KDM4EHSD17B10 | |
| SCHEMBL188641 | 0.78 | HPGD (0.47) | KMT2AHTTGRM5KDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12312339-B2 | Polo like kinase 4 inhibitors | ORIC PHARMACEUTICALS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-20240270722-A1 | POLO LIKE KINASE 4 INHIBITORS | ORIC PHARMACEUTICALS, INC. | 2024-08-15 | — | — | US | disclosed |
| CN-114245796-B | Imidazo [1,2-a ] pyridinyl derivatives and their use in the treatment of diseases | 比奥根MA公司 | 2024-07-30 | — | — | CN | disclosed |
| US-20240246964-A1 | SUBSTITUTED 1-ARYL-1’-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1’-BIHETEROARYL COMPOUNDS, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-25 | — | — | US | disclosed |
| US-RE49931-E1 | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-04-23 | — | — | US | disclosed |
| US-20240124426-A1 | POLO LIKE KINASE 4 INHIBITORS | ORIC PHARMACEUTICALS, INC. | 2024-04-18 | — | — | US | disclosed |
| US-RE49893-E1 | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-04-02 | — | — | US | disclosed |
| CN-117794529-A | POLO-like kinase 4 inhibitors | 欧瑞克制药公司 | 2024-03-29 | — | — | CN | disclosed |
| US-RE49880-E1 | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-03-26 | — | — | US | disclosed |
| EP-4337198-A1 | POLO LIKE KINASE 4 INHIBITORS | Oric Pharmaceuticals, Inc. (US) | 2024-03-20 | — | — | EP | disclosed |
| US-20100075965-A1 | PI3 KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG | 2010-03-25 | — | — | US | disclosed |
| US-20100075965-A1 | PI3 KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG | 2010-03-25 | — | — | US | disclosed |
| CN-101384586-A | PI-3 kinase inhibitors and methods of use thereof | NOVARTIS AG (CH) | 2009-03-11 | — | — | CN | disclosed |
| EP-1989201-A1 | PI-3 KINASE INHIBITORS AND METHODS OF THEIR USE | Novartis AG (CH) | 2008-11-12 | — | — | EP | disclosed |
| WO-2007095588-A1 | PI-3 KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2007-08-23 | — | — | WO | disclosed |
| WO-2007095588-A1 | PI-3 KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2007-08-23 | — | — | WO | disclosed |
| US-20070027321-A1 | Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5 | MERCK SHARP & DOHME CORP. | 2007-02-01 | — | — | US | disclosed |
| CN-1845915-A | Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5 | MERCK & CO INC (US) | 2006-10-11 | — | — | CN | disclosed |
| EP-1664018-A1 | BIPYRIDYL AMINES AND ETHERS AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | Merck & Co., Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005021529-A1 | BIPYRIDYL AMINES AND ETHERS AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO., INC. (US) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124426-A1 | POLO LIKE KINASE 4 INHIBITORS | PLK4, PLK2, PLK3 | KMT2A 1756/4885HTT 4049/4885TLR8 4015/4885 |
| US-20100075965-A1 | PI3 KINASE INHIBITORS AND METHODS OF THEIR USE | PIK3CA, PIK3CD, PIK3CB | KMT2A 3484/4885HTT 4136/4885TLR8 3391/4885 |
| US-20070027321-A1 | Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5 | GRM5, GRIK5, GRM1 | KMT2A 721/4885HTT 2004/4885TLR8 1859/4885 |
| US-12312339-B2 | Polo like kinase 4 inhibitors | PLK4, PLK2, PLK3 | KMT2A 1756/4885HTT 4049/4885TLR8 4015/4885 |
| US-20240246964-A1 | SUBSTITUTED 1-ARYL-1’-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1’-BIHETEROARYL COMPOUNDS, AND METHODS USING SAME | HAVCR2, HDGF, HCCS | KMT2A 933/4885HTT 1210/4885TLR8 1116/4885 |
| US-20240270722-A1 | POLO LIKE KINASE 4 INHIBITORS | PLK4, PLK2, PLK3 | KMT2A 1806/4885HTT 4085/4885TLR8 3991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.